<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787692</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-20-0549</org_study_id>
    <nct_id>NCT04787692</nct_id>
  </id_info>
  <brief_title>Impact of Daily, Digital and Behavioral Tele-health Tapering Program for Perioperative Surgical Patients Exposed to Opioids and Benzodiazepines.</brief_title>
  <official_title>Impact of Daily, Digital and Behavioral Tele-health Tapering Program for Perioperative Surgical Patients Exposed to Opioids and Benzodiazepines.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety, acceptability, and feasibility of a&#xD;
      controlled taper off of opioids and/or benzodiazepines, with the use of behavioral health&#xD;
      tele-health based therapy services, in the perioperative patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients that engage and participate in the process</measure>
    <time_frame>30 days post intervention</time_frame>
    <description>Engagement and participation are defined as patient's commitment for 1 hour a week as scheduled.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients that engage and participate in the process</measure>
    <time_frame>90 days post intervention</time_frame>
    <description>Engagement and participation are defined as patient's commitment for 1 hour a week as scheduled.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients that engage and participate in the process</measure>
    <time_frame>180 days post intervention</time_frame>
    <description>Engagement and participation are defined as patient's commitment for 1 hour a week as scheduled.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in the naive group that successfully taper off of the benzodiazepine or opioid</measure>
    <time_frame>30 days post intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in the naive group that successfully taper off of the benzodiazepine or opioid</measure>
    <time_frame>90 days post intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in the tolerant group that successfully taper off of the benzodiazepine or opioid</measure>
    <time_frame>180 days post intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional well-being as measured by the Generalized Anxiety Disorder 7-item (GAD-7) scale</measure>
    <time_frame>30 days post intervention</time_frame>
    <description>The Generalized Anxiety Disorder 7-item (GAD-7) scale has 7 questions each ranging in score from 0-3, with a higher score indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional well-being as measured by the The Patient Health Questionnaire 9 (PHQ-9)</measure>
    <time_frame>30 days post intervention</time_frame>
    <description>The Patient Health Questionnaire 9 (PHQ-9) consists of 10 questions with a total score ranging form 1 to 27, with a higher score indicating greater depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms as measured by the Edmonton Symptom Assessment System (ESAS)</measure>
    <time_frame>30 days post intervention</time_frame>
    <description>The Edmonton Symptom Assessment System consists of 10 questions, each question ranging from 0-10, with a higher score indicating a worse outcome. The ESAS rates the intensity of common symptoms, including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional well-being as measured by the Generalized Anxiety Disorder 7-item (GAD-7) scale</measure>
    <time_frame>90 days post intervention</time_frame>
    <description>The Generalized Anxiety Disorder 7-item (GAD-7) scale has 7 questions each ranging in score from 0-3, with a higher score indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional well-being as measured by the Patient Health Questionnaire 9 (PHQ-9)</measure>
    <time_frame>90 days post intervention</time_frame>
    <description>The Patient Health Questionnaire 9 (PHQ-9) consists of 10 questions with a total score ranging form 1 to 27, with a higher score indicating greater depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Well-Being as measured by the Edmonton Symptom Assessment System (ESAS)</measure>
    <time_frame>90 days post intervention</time_frame>
    <description>The Edmonton Symptom Assessment System consists of 10 questions, each question ranging from 0-10, with a higher score indicating a worse outcome. The ESAS rates the intensity of common symptoms, including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional well-being as measured by the Generalized Anxiety Disorder 7-item (GAD-7) scale</measure>
    <time_frame>180 days post intervention</time_frame>
    <description>The Generalized Anxiety Disorder 7-item (GAD-7) scale has 7 questions each ranging in score from 0-3, with a higher score indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional well-being as measured by the Patient Health Questionnaire 9 (PHQ-9)</measure>
    <time_frame>180 days post intervention</time_frame>
    <description>The Patient Health Questionnaire 9 (PHQ-9) consists of 10 questions with a total score ranging form 1 to 27, with a higher score indicating greater depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Well-Being as measured by the Edmonton Symptom Assessment System (ESAS)</measure>
    <time_frame>180 days post intervention</time_frame>
    <description>The Edmonton Symptom Assessment System consists of 10 questions, each question ranging from 0-10, with a higher score indicating a worse outcome. The ESAS rates the intensity of common symptoms, including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the Quality of life Score</measure>
    <time_frame>30 days post intervention</time_frame>
    <description>The range of scores is between 15 to 105, with a higher score or number being indicative of a higher quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the Quality of life Score</measure>
    <time_frame>90 days post intervention</time_frame>
    <description>The range of scores is between 15 to 105, with a higher score or number being indicative of a higher quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the Quality of life Score</measure>
    <time_frame>180 days post intervention</time_frame>
    <description>The range of scores is between 15 to 105, with a higher score or number being indicative of a higher quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Elective Spine Surgery Receiving Pre and/or Postoperative Pain Control With Opioids</condition>
  <arm_group>
    <arm_group_label>Opioid and Benzodiazepine Naive-patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Opioid and Benzodiazepine Naive-patients, defined as no medications 30 days prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opioid and Benzodiazepine Tolerant-patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Opioid and Benzodiazepine Tolerant-patients, defined as use of medications on most days for 1 or more months (&gt;30 days) prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Opioid and Benzodiazepine Naive-patients</intervention_name>
    <description>Duration of treatment : 1 month Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT &amp; MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, Cognitive behavioral therapy(CBT), Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.</description>
    <arm_group_label>Opioid and Benzodiazepine Naive-patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Opioid and Benzodiazepine Tolerant-patients</intervention_name>
    <description>Duration of treatment : 6 months Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT &amp; MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, CBT, Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.</description>
    <arm_group_label>Opioid and Benzodiazepine Tolerant-patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Preoperative benzodiazepines opioid dependence (daily use of opioids or&#xD;
             benzodiazepines preoperatively) (Naive: No Meds 30 Days Prior to surgery,Opioid&#xD;
             tolerant/dependant: Use of Meds on Most Days For 1 or more months prior to surgery)&#xD;
&#xD;
          -  Subject willing to use Lucid Lane program to provide behavioral health support&#xD;
             perioperative period up to 6 months post-op for tolerant opioid/benzo users&#xD;
&#xD;
          -  Subject is willing to discuss Lucid Lane progress with the University of Texas Health&#xD;
             Science Center(UTHealth) perioperative team and prescribing clinicians&#xD;
&#xD;
          -  Subject is willing to sign a Lucid Lane Client Agreement&#xD;
&#xD;
          -  Willing to sign an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious mental illnesses including schizophrenia-spectrum disorders, severe bipolar&#xD;
             disorder, and severe major depression.&#xD;
&#xD;
          -  Active suicidal ideations&#xD;
&#xD;
          -  Patients on methadone or buprenorphine for treatment of opioid use disorder (i.e. for&#xD;
             treatment of addiction, and not for treatment of pain)&#xD;
&#xD;
          -  Patient unwilling to use or not possessing access to a device that allows for video&#xD;
             visits (e.g. a smartphone, tablet, or computer)&#xD;
&#xD;
          -  Patients who are on palliative care&#xD;
&#xD;
          -  Insufficient ability to use English to participate in the consent process, the&#xD;
             intervention or study assessments.&#xD;
&#xD;
          -  Insufficient ability to provide informed consent to participate&#xD;
&#xD;
          -  If the patient misses more than 2 lucid lane sessions per week, the staff will be&#xD;
             immediately notified by Lucid Lane.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan G Pivalizza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evan G Pivalizza, MD</last_name>
    <phone>(713) 500-6251</phone>
    <email>Evan.G.Pivalizza@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johanna De Haan</last_name>
    <phone>(713) 500-6200</phone>
    <email>Johanna.B.DeHaan@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan G Pivalizza, MD</last_name>
      <phone>713-500-6251</phone>
      <email>Evan.G.Pivalizza@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Johanna De Haan, MD</last_name>
      <phone>(713) 500-6200</phone>
      <email>Johanna.B.DeHaan@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Evan Pivalizza</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Opioid taper</keyword>
  <keyword>post-surgery</keyword>
  <keyword>behavioral tele-health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

